What is the medical insurance reimbursement price of sorafenib? How much does the patient need to pay out of pocket after being reimbursed by medical insurance?

As an important targeted therapy drug, Sorafenib has been launched in China and has been included in medical insurance reimbursement items to facilitate patient treatment. The specifications of the original research version of sorafenib on the domestic market are 0.2*60 tablets, and the market price per box is about 6000 yuan. As a drug used to treat liver cancer, kidney cancer and other cancers, the price of sorafenib may bring a certain financial burden to many patients. However, due to the reimbursement policy of medical insurance, patients can reduce financial pressure after reimbursement.

For sorafenib, which has been included in medical insurance, the specific medical insurance reimbursement price will vary according to the patient's region and the reimbursement policies of local hospitals. Generally speaking, after medical insurance reimburses, the out-of-pocket portion that patients need to pay will be significantly reduced. For the specific out-of-pocket amount, patients need to consult the local hospital pharmacy. According to the medical insurance reimbursement ratio, it is generally between 50% and 80%, which means that the actual expenses borne by most patients are greatly reduced after receiving medical insurance reimbursement.

Although the original drug of sorafenib is more expensive, there are also some generic versions in overseas markets with relatively lower prices. It is understood that the price of generic drugs of sorafenib in overseas markets ranges from about 500-1000 yuan. These generic drugs are almost the same as the original drugs in terms of ingredients and efficacy, so they have become the choice of some patients when they are under great financial pressure. The price of generic drugs is significantly lower than that of original drugs, but their quality and efficacy have been widely recognized, and patients can choose to purchase them based on their own economic status.

Overall, although the original drug price of sorafenib is relatively high, the medical insurance reimbursement policy has greatly reduced the financial burden on patients. Generic drugs are also a relatively affordable option for patients on a budget. Patients can consult the hospital or pharmacy to understand the specific reimbursement policy and self-pay portion, so as to make a reasonable choice.

Reference materials:https://www.nexavar.com/